Pharmacogenetic Analysis of BR

Slides:

Advertisements

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib Suzanne Jenkins, DPhil, James Chih-Hsin.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation Jean-Yves.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer Peter M. Ellis, MBBS,

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure Jessamy A. Boyd, MD, Jessica L. Hubbs,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Prevention and Management of Bone Metastases in Lung Cancer: A Review

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

George Blumenschein, MD, John V. Heymach, MD, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Maria Q. Baggstrom, MD, Saiama N. Waqar, MD, Ananth K

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Erratum Journal of Thoracic Oncology

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? Charles Lim, MD, Mike Sung, BSc,

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Anne S. Tsao, MD, Suyu Liu, PhD, J. Jack Lee, PhD, Christine M

The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm.

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non- small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non- small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan.

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled.

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

European Lung Cancer Conference (ELCC) 2016 Organisation

OA Video-Assisted Thoracoscopic Surgery vs

Regina M. Vidaver, PhD, Beth S. Schachter, PhD

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia.

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer Giorgio.

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

Pharmacogenetic Analysis of BR Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer Geoffrey Liu, MD, FRCPC, D. Cheng, MD, PhD, K. Ding, PhD, A. Le Maitre, MSc, N. Liu, MSc, D. Patel, BSc, Z. Chen, MD, PhD, L. Seymour, MD, PhD, F.A. Shepherd, MD, FRCPC, M.S. Tsao, MD, FRCPC Journal of Thoracic Oncology Volume 7, Issue 2, Pages 316-322 (February 2012) DOI: 10.1097/JTO.0b013e31824166c1 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Biospecimens available and analyzed from BR.21 trial. Samples were not available for release because the samples either had been used up in prior translational analyses (e.g., mutational analysis, in situ hybridization, immunohistochemical analysis, and gene expression analyses) or were deemed to have inadequate remaining tissue for the present analysis. Most of these samples were from cases in which slides (rather than blocks) had been provided by the originating pathology department. Failed genotyping refers to failure of the genotyped result to meet quality control standard, including failure of replication during duplicate genotyping or uninterpretable genotyping results despite repeated testing. Journal of Thoracic Oncology 2012 7, 316-322DOI: (10.1097/JTO.0b013e31824166c1) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions